Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.77 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.77 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.77 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.77 |
| ▸ | F2 | P00734 | 3/20 | 0.68 |
| ▸ | PPARG | P37231 | 1/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | F10 | P00742 | 2/20 | 0.57 |
| ▸ | PLG | P00747 | 2/20 | 0.57 |
| ▸ | PLAU | P00749 | 2/20 | 0.57 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29784265 | 1.00 | CASP3 (0.77) | CASP3SENP8SENP7SENP6F2 | |
| SCHEMBL23717137 | 0.87 | F2 (0.64) | CASP3SENP8SENP7SENP6F2 | |
| SCHEMBL11688369 | 0.87 | F2 (0.64) | CASP3SENP8SENP7SENP6F2 | |
| SCHEMBL29941485 | 0.87 | CASP3 (1.00) | CASP3SENP8SENP7SENP6F2 | |
| SCHEMBL3704691 | 0.87 | CASP3 (1.00) | CASP3SENP8SENP7SENP6F2 | |
| SCHEMBL11565448 | 0.86 | CHEK2 (0.67) | CASP3SENP8SENP7SENP6F2 | |
| SCHEMBL4334503 | 0.86 | CASP3 (0.57) | CASP3SENP8SENP7SENP6F2 | |
| SCHEMBL164956 | 0.86 | CASP3 (0.57) | CASP3SENP8SENP7SENP6F2 | |
| SCHEMBL693160 | 0.86 | F2 (0.58) | CASP3SENP8SENP7SENP6F2 | |
| SCHEMBL11563588 | 0.86 | CASP3 (0.57) | CASP3SENP8SENP7SENP6F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3694840-B1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-08-04 | — | — | EP | disclosed |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-9815784-B2 | CC-1065 analogs and their conjugates | SYNTARGA B.V. (NL) | 2017-11-14 | — | — | US | disclosed |
| US-20110207767-A1 | Novel cc-1065 Analogs and Their Conjugates | BYONDIS B.V. (NL) | 2011-08-25 | — | — | US | disclosed |
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2011-01-27 | — | — | US | disclosed |
| CN-101910121-A | Bis (sulfonylamino) derivatives 066 in therapy | ASTRAZENECA AB | 2010-12-08 | — | — | CN | disclosed |
| EP-2217566-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 | AstraZeneca AB (SE) | 2010-08-18 | — | — | EP | disclosed |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| CN-100443469-C | Viral polymerase inhibitors | BOEHRINGER INGELHEIM CA LTD (CA) | 2008-12-17 | — | — | CN | disclosed |
| CN-101302182-A | Virus polymerase inhibitors | BOEHRINGER INGELHEIM CA LTD (CA) | 2008-11-12 | — | — | CN | disclosed |
| CN-1610546-A | Viral polymerase inhibitors | BOEHRINGER INGELHEIM CA LTD (CA) | 2005-04-27 | — | — | CN | disclosed |
| EP-0854865-B1 | COMBINATORIAL SOLID PHASE SYNTHESIS OF A LIBRARY OF INDOLE DERIVATIVES | PHARMACIA ITALIA SPA (IT) | 2003-01-29 | — | — | EP | disclosed |
| US-5856496-A | Combinatorial solid phase synthesis of a library of indole derivatives | PHARMACIA & UPJOHN S.P.A. (IT) | 1999-01-05 | — | — | US | disclosed |
| EP-0854865-A1 | COMBINATORIAL SOLID PHASE SYNTHESIS OF A LIBRARY OF INDOLE DERIVATIVES | PHARMACIA & UPJOHN S.p.A. (IT) | 1998-07-29 | — | — | EP | disclosed |
| WO-1997044319-A1 | COMBINATORIAL SOLID PHASE SYNTHESIS OF A LIBRARY OF INDOLE DERIVATIVES | PHARMACIA & UPJOHN S.P.A. (IT) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | PTGER1, CYP3A5, SULT1E1 | CASP3 3085/4885SENP8 2807/4885SENP7 2870/4885 |
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | MAGI3, PYM1, MAG | CASP3 4280/4885SENP8 4307/4885SENP7 4113/4885 |
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | CYP2D6, PTGER1, CYP2B6 | CASP3 2919/4885SENP8 3312/4885SENP7 3189/4885 |
| US-20110207767-A1 | Novel cc-1065 Analogs and Their Conjugates | PCNA, CDC5L, TOP1 | CASP3 933/4885SENP8 1836/4885SENP7 1131/4885 |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | MAGI3, PYM1, MAG | CASP3 4280/4885SENP8 4307/4885SENP7 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.